1. Home
  2. AORT vs IMTX Comparison

AORT vs IMTX Comparison

Compare AORT & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Artivion Inc.

AORT

Artivion Inc.

HOLD

Current Price

$26.88

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

IMTX

Immatics N.V.

HOLD

Current Price

$9.35

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AORT
IMTX
Founded
1984
N/A
Country
United States
Germany
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.3B
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
AORT
IMTX
Price
$26.88
$9.35
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
6
Target Price
$49.40
$19.00
AVG Volume (30 Days)
719.0K
541.4K
Earning Date
05-07-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
165.62
N/A
EPS
N/A
N/A
Revenue
$298,836,000.00
N/A
Revenue This Year
$14.20
N/A
Revenue Next Year
$11.20
$25.91
P/E Ratio
N/A
N/A
Revenue Growth
18.01
N/A
52 Week Low
$19.16
$5.05
52 Week High
$48.25
$12.41

Technical Indicators

Market Signals
Indicator
AORT
IMTX
Relative Strength Index (RSI) 49.27 53.55
Support Level $25.79 $9.37
Resistance Level $28.29 $10.41
Average True Range (ATR) 1.15 0.43
MACD -0.31 0.05
Stochastic Oscillator 20.02 73.42

Price Performance

Historical Comparison
AORT
IMTX

About AORT Artivion Inc.

Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.

About IMTX Immatics N.V.

Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.

Share on Social Networks: